Your browser doesn't support javascript.
loading
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer, Robert J; Rini, Brian I; McDermott, David F; Arén Frontera, Osvaldo; Hammers, Hans J; Carducci, Michael A; Salman, Pamela; Escudier, Bernard; Beuselinck, Benoit; Amin, Asim; Porta, Camillo; George, Saby; Neiman, Victoria; Bracarda, Sergio; Tykodi, Scott S; Barthélémy, Philippe; Leibowitz-Amit, Raya; Plimack, Elizabeth R; Oosting, Sjoukje F; Redman, Bruce; Melichar, Bohuslav; Powles, Thomas; Nathan, Paul; Oudard, Stéphane; Pook, David; Choueiri, Toni K; Donskov, Frede; Grimm, Marc-Oliver; Gurney, Howard; Heng, Daniel Y C; Kollmannsberger, Christian K; Harrison, Michael R; Tomita, Yoshihiko; Duran, Ignacio; Grünwald, Viktor; McHenry, M Brent; Mekan, Sabeen; Tannir, Nizar M.
Affiliation
  • Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org.
  • Rini BI; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • McDermott DF; Department of Hematology and Medical Oncology, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
  • Arén Frontera O; Department of Medical Oncology, Centro de Invetigación Clínica Bradford Hill, Santiago, Chile.
  • Hammers HJ; Department of Oncology and Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Carducci MA; Department of Oncology and Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Salman P; Department of Medical Oncology, Fundación Arturo López Pérez, Santiago, Chile.
  • Escudier B; Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  • Beuselinck B; Department of Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Amin A; Levine Cancer Institute, Atrium Healthcare, Charlotte, NC, USA.
  • Porta C; Department of Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy.
  • George S; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Neiman V; Department of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; Tel Aviv University, Tel Aviv, Israel.
  • Bracarda S; Department of Oncology, Ospedale San Donato, Azienda USL Toscana Sud-Est, IstitutoToscanoTumori, Arezzo, Italy.
  • Tykodi SS; Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Barthélémy P; Department of Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Leibowitz-Amit R; Oncology Department, Sheba Medical Center, Ramat Gan, Israel.
  • Plimack ER; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Oosting SF; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
  • Redman B; Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
  • Melichar B; Department of Oncology, Palacky University, and University Hospital Olomouc, Olomouc, Czech Republic.
  • Powles T; Department of Genitourinary Oncology, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust, London, UK.
  • Nathan P; Department of Cancer Services: Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
  • Oudard S; Department of Medical Oncology, Service de Cancérologie Médicale Hôpital Européen Georges Pompidou, Paris, France.
  • Pook D; Department of Oncology, Monash Health, Melbourne, VIC, Australia.
  • Choueiri TK; Department of Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Donskov F; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Grimm MO; Department of Urology, Jena University Hospital, Jena, Germany.
  • Gurney H; Department of Medical Oncology, Westmead Hospital and Macquarie University, Sydney, NSW, Australia.
  • Heng DYC; Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.
  • Kollmannsberger CK; Department of Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Harrison MR; Division of Medical Oncology, Duke Cancer Institute, Durham, NC, USA.
  • Tomita Y; Department of Urology, Niigata University, Niigata, Japan.
  • Duran I; Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain.
  • Grünwald V; Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, University Hospital Essen, Essen, Germany.
  • McHenry MB; Bristol-Myers Squibb, Princeton, NJ, USA.
  • Mekan S; Bristol-Myers Squibb, Princeton, NJ, USA.
  • Tannir NM; Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Lancet Oncol ; 20(10): 1370-1385, 2019 10.
Article in En | MEDLINE | ID: mdl-31427204
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Sunitinib / Kidney Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Sunitinib / Kidney Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2019 Type: Article